Biopharmaceutical company GSK plc (LSE/NYSE:GSK) confirmed on Tuesday that it is appealing a Delaware court decision allowing plaintiff expert testimony in the ongoing Zantac (ranitidine) litigation.
The company argues that the ruling contradicts how the Daubert standard is typically applied and could impact all Delaware businesses.
GSK, joined by Pfizer (NYSE:PFE), Sanofi (Euronext Paris:SAN) (Nasdaq:SNY) and Boehringer Ingelheim, has filed with the Delaware Supreme Court seeking to overturn the lower court's decision. GSK maintains that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer.
A decision on whether to grant interlocutory review and hear the appeal is expected later this year.
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
Novartis receives positive CHMP opinion for Kisqali
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
SHINE Technologies collaboration could result in new kidney and prostate cancer treatments
Shenzhen Chipscreen Biosciences' IND application for CS231295 tablets accepted in China
Sanofi and Orano partner to advance radioligand therapies
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial
Viatris signs exclusive licensing agreement with Lexicon Pharmaceuticals
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
RaySearch secures RayStation orders from French cancer centers under Unicancer agreement
Merck's CAPVAXIVE shows promising immune responses in adults at risk of pneumococcal disease
HUTCHMED's TAGRISSO plus ORPATHYS shows promise in lung cancer treatment
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient